Ownership and insider activity for Lineage Cell Therapeutics, Inc. (LCTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter c...
Price
| Price | $1.07 |
| Market Cap | $267M |
| Exchange | AMEX |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.1M | $36.8M | $23.6M | $9.5M | $32.6M | $55.7M | $11.4M | $35.4M | $45.8M | $40.8M |
| Short-term Investments | $627000 | $1.3M | $7.2M | $21.2M | $9.0M | $2.6M | $46.5M | $50000 | $2.0M | $15.0M |
| Receivables | $1.2M | $3.0M | $3.7M | $24.7M | $4000 | $51.1M | $297000 | $745000 | $638000 | $1.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $25.6M | $42.6M | $36.4M | $57.5M | $44.0M | $111.5M | $60.0M | $38.4M | $51.0M | $59.2M |
| Property, Plant & Equipment | $5.5M | $5.5M | $5.8M | $8.2M | $5.6M | $4.9M | $5.7M | $4.8M | $4.4M | $4.7M |
| Goodwill | 0 | 0 | 0 | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M |
| Intangible Assets | $10.2M | $6.9M | $3.1M | $48.2M | $47.0M | $46.8M | $46.7M | $46.6M | $46.5M | $31.7M |
| Total Assets | $142.6M | $173.2M | $101.7M | $125.5M | $107.9M | $174.5M | $123.7M | $101.0M | $113.2M | $112.6M |
| Accounts Payable | $1.6M | $938000 | $2.4M | $2.4M | $2.6M | $3.5M | $2.4M | $2.0M | $1.2M | $2.3M |
| Short-term Debt | $932000 | $152000 | $70000 | $1.2M | $523000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $8.8M | $6.9M | $6.8M | $6.5M | $7.8M | $47.1M | $19.0M | $18.0M | $14.0M | $11.4M |
| Long-term Debt | $1.2M | $18000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $12.1M | $9.0M | $9.4M | $14.2M | $12.8M | $83.6M | $51.7M | $39.0M | $36.2M | $69.2M |
| Retained Earnings | -$196.3M | -$216.3M | -$261.9M | -$273.4M | -$294.1M | -$337.1M | -$363.4M | -$384.9M | -$403.5M | -$467.0M |
| Total Equity | $117.9M | $162.6M | $93.8M | $113.0M | $96.2M | $92.2M | $73.3M | $63.4M | $78.4M | $44.5M |
| Total Debt | $4.0M | $1.5M | $2.3M | $5.2M | $3.8M | $2.8M | $3.9M | $3.0M | $2.5M | $2.4M |
| Net Debt | -$18.7M | -$36.6M | -$28.5M | -$25.5M | -$37.7M | -$55.6M | -$54.0M | -$32.5M | -$45.3M | -$53.4M |
| Working Capital | $16.8M | $35.7M | $29.5M | $51.0M | $36.2M | $64.4M | $41.0M | $20.5M | $37.0M | $47.8M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 6.61 |
Profitability
| Return on Equity | -71.14% |
| Return on Invested Capital | -23.25% |
| Return on Assets | -30.37% |
| Gross Margin | 96.59% |
| Operating Margin | -205.23% |
| Net Margin | -246.58% |
Related companies: ADCT · AUTL · BNTC · FULC · GALT · NGNE · OCGN
Explore sector: Healthcare · Biotechnology
More sections of LCTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks